Cyclerion Therapeutics (NASDAQ:CYCN) Shares Up 0.6% – Here’s What Happened

Posted by Brian Himes on Jun 23rd, 2026

Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Get Free Report)’s stock price was up 0.6% on Monday . The stock traded as high as $3.28 and last traded at $3.22. Approximately 20,180 shares changed hands during mid-day trading, a decline of 29% from the average session volume of 28,300 shares. The stock had previously closed at $3.20.

Analysts Set New Price Targets

Separately, Weiss Ratings raised shares of Cyclerion Therapeutics from a “sell (e+)” rating to a “sell (d-)” rating in a research note on Wednesday, April 29th. One research analyst has rated the stock with a Sell rating, Based on data from MarketBeat.com, the stock has an average rating of “Sell”.

Check Out Our Latest Stock Report on Cyclerion Therapeutics

Cyclerion Therapeutics Stock Up 0.6%

The stock has a 50-day moving average of $3.10 and a 200 day moving average of $2.18. The stock has a market cap of $13.94 million, a PE ratio of -2.37 and a beta of 1.79.

Cyclerion Therapeutics (NASDAQ:CYCN – Get Free Report) last issued its earnings results on Tuesday, May 12th. The company reported ($0.76) earnings per share (EPS) for the quarter, beating the consensus estimate of ($17.20) by $16.44. Cyclerion Therapeutics had a negative return on equity of 62.10% and a negative net margin of 170.11%. Research analysts forecast that Cyclerion Therapeutics, Inc. will post -1.2 EPS for the current fiscal year.

Institutional Trading of Cyclerion Therapeutics

A hedge fund recently bought a new stake in Cyclerion Therapeutics stock. Two Sigma Investments LP acquired a new position in Cyclerion Therapeutics, Inc. (NASDAQ:CYCN – Free Report) in the 3rd quarter, according to its most recent filing with the Securities & Exchange Commission. The institutional investor acquired 13,293 shares of the company’s stock, valued at approximately $31,000. Two Sigma Investments LP owned 0.40% of Cyclerion Therapeutics as of its most recent filing with the Securities & Exchange Commission. 75.62% of the stock is currently owned by institutional investors and hedge funds.

About Cyclerion Therapeutics

(Get Free Report)

Cyclerion Therapeutics, Inc is a clinical-stage biopharmaceutical company focused on the discovery and development of inhibitors and stimulators of soluble guanylate cyclase (sGC), an intracellular enzyme that plays a critical role in the regulation of vascular tone, cellular proliferation and inflammation. By targeting the nitric oxide (NO)–sGC–cyclic guanosine monophosphate (cGMP) signaling pathway, Cyclerion aims to address a range of cardiometabolic, cardiovascular, pulmonary and neurological disorders with significant unmet medical need.

The company’s lead program, praliciguat, is an oral sGC stimulator investigated for indications such as diabetic nephropathy, metabolic syndrome and heart failure with preserved ejection fraction.